O
IRWD icon

OrbiMed’s Ironwood Pharmaceuticals IRWD Stock Holding History

OrbiMed’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-179,100
Closed -$2.77M – 140
2018
Q3 		$2.77M Hold
179,100
– – 0.03% 137
2018
Q2 		$2.87M Hold
179,100
– – 0.03% 138
2018
Q1 		$2.31M Sell
179,100
-298,500
-63% -$3.72M 0.03% 130
2017
Q4 		$6M Buy
+477,600
New +$6.24M 0.08% 112
2014
Q3 		– Sell
-358,200
Closed -$4.6M – 138
2014
Q2 		$4.6M Hold
358,200
– – 0.05% 114
2014
Q1 		$3.7M Buy
+358,200
New +$4.03M 0.05% 124

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

OrbiMed's IRWD Position: Q1 2019 in Review

OrbiMed sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2019, closing a stake of 3,436,332 shares — an estimated $29.8M sold.

OrbiMed first reported a position in IRWD in Q1 2014 and held it in 20 quarters. The position peaked at $192M in Q1 2015. 156 funds tracked by Wall St. Rank hold IRWD as of Q1 2019.

  • OrbiMed reported no remaining Ironwood Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • OrbiMed sold 3,436,332 Ironwood Pharmaceuticals shares in Q1 2019, an estimated $29.8M.
  • OrbiMed first reported a position in Ironwood Pharmaceuticals in Q1 2014 and held it in 20 quarters.
  • OrbiMed's Ironwood Pharmaceuticals position peaked at $192M in Q1 2015.
  • 156 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2019.

Based on OrbiMed's 13F filing for Q1 2019, filed 15 May 2019.